anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Geriatric patients are at increased risk for developing severe tendon disorders including tendon rupture when being treated with a fluoroquinolone such as LEVAQUIN®. This risk is further increased in patients receiving concomitant corticosteroid therapy. Tendinitis or tendon rupture can involve the Achilles, hand, shoulder, or other tendon sites and can occur during or after completion of therapy; cases occurring up to several months after fluoroquinolone treatment have been reported. Caution should be used when prescribing LEVAQUIN® to elderly patients especially those on corticosteroids. Patients should be informed of this potential side effect and advised to discontinue LEVAQUIN® and contact their healthcare provider if any symptoms of tendinitis or tendon rupture occur [see Boxed Warning; Warnings and Precautions (5.1); and Adverse Reactions (6.3)].

In phase 3 clinical trials, 1,945 LEVAQUIN®-treated patients (26%) were ≥ 65 years of age. Of these, 1,081 patients (14%) were between the ages of 65 and 74 and 864 patients (12%) were 75 years or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.

Severe, and sometimes fatal, cases of hepatotoxicity have been reported post-marketing in association with LEVAQUIN®. The majority of fatal hepatotoxicity reports occurred in patients 65 years of age or older and most were not associated with hypersensitivity. LEVAQUIN® should be discontinued immediately if the patient develops signs and symptoms of hepatitis [see Warnings and Precautions (5.4)].

Elderly patients may be more susceptible to drug-associated effects on the QT interval. Therefore, precaution should be taken when using LEVAQUIN® with concomitant drugs that can result in prolongation of the QT interval (e.g., Class IA or Class III antiarrhythmics) or in patients with risk factors for torsade de pointes (e.g., known QT prolongation, uncorrected hypokalemia) [see Warnings and Precautions (5.8)].

The pharmacokinetic properties of levofloxacin in younger adults and elderly adults do not differ significantly when creatinine clearance is taken into consideration. However, since the drug is known to be substantially excreted by the kidney, the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Clinical Pharmacology (12.3)].
Apply a thin layer of Florexa, to wanted areas of the face and adjacent involved areas under the chin and rub in thoroughly. Do not wash treated area for at least 4 hours. Use twice daily at least 8 hours apart or as directed by a physician. The patient should continue to use hair removal techniques as needed in conjunction with Florexa. ( Florexa should be applied at least 5 minutes after hair removal.) Cosmetics or sunscreens may be applied over treated areas; you should wait a few minutes to allow the treatment to be absorbed. 

  
Florexa doesn't permanently remove hair or "cure" unwanted facial hair. It is not a depilatory. Your treatment program should include continuation of any hair removal technique you are currently using. Florexa will help you manage your condition and improve your appearance. 

Improvement in the condition occurs gradually. Don't be discouraged if you see no immediate improvement. Be patient. Improvement may be seen as early as 4 to 8 weeks of treatment. Improvement may take longer in some individuals. If no improvement is seen after 6 months of use; discontinue use.
This group will be given a pedometer following radical prostatectomy. Subjects in the experimental group will have a graduated step-count goal as follows: POD 0-2: 2,000/day. POD 3-6: 3,000/day. POD 7-9: 4,000/day. POD 10-14: 5,000/day.
Patients will be followed by a dietician at the patient's home at weeks 2 (S2) and 4 (S4) of radiotherapy, then at the end of radiotherapy at T0. Monitoring will be continued 15 days after the end of irradiation and then one month (T1 and 2 months (T2). A personalized follow will be performed and a document entitled "Dietary own program" will be given to the patient.
Prostate cancer (PCa) represents the most common noncutaneous cancer and second most common cause of cancer related death among men in the United States and worldwide. Individual PCa tumor behavior is variable. Some tumors show slow indolent growth patterns and may never become clinically significant while others are aggressive and lead to metastases and death. PCa most commonly metastasizes to bone and lymph nodes. Lungs, liver, and adrenal glands are less frequent metastatic sites.

Accurate staging and risk stratification is essential to optimal management. Pelvic lymph node dissection (PLND) which is performed along with radical prostatectomy is the gold standard for detection of occult nodal metastases but is invasive and has associated morbidity. PLND offers an additional therapeutic benefit in some patients, but is also associated with potential complications and can still underestimate the extent of nodal metastases as 40-50% fall outside the traditional dissection zones \[6\]. Furthermore, fewer patients are presenting with nodal metastases at initial presentation due to stage migration, so more PLNDs need to be performed to benefit one patient. Therefore there is a clear need for noninvasive imaging options to assist with early and accurate detection of nodal metastases.

68Ga PSMA-HBED-CC is a urea-based small molecular inhibitor that targets an enzymatic site on the extracellular domain of the PSMA membrane protein. Based on strong preclinical evidence, a number of clinical studies of 68Ga PSMA-HBED-CC PET/CT have been performed. Afshar-Oromieh et al. showed detection of lesions suspicious for PCa metastases in 84% of a cohort of patients (n=37) being investigated for biochemical relapse, clarification of suspicious findings on other modalities, or evaluation for possible 131I PSMA ligands. In a larger retrospective study (n=319) Afshar-Oromieh et al. showed that 68Ga PSMA-HBED-CC PET/CT detected PCa in 83% of patients with suspected recurrence. In another study Afshar-Oromieh et al compared 68Ga PSMA-HBED-CC PET/CT to 18F fluoromethylcholine (FCH) PET/CT. At least one PCa lesion was detected in 87% of patients with 68Ga PSMA-HBED-CC versus 70% of patients with 18F FCH. Among patients in whom PSA values were \<2.82 ng/ml at least one lesion could be detected in 69% of patients with 68Ga PSMA-HBED-CC and 44% patients with 18F FCH. Tumor-to-background ratios were higher for 68Ga PSMA-HBED-CC. In the aforementioned studies by Afshar-Oromieh et al. 49 patients with positive scans were further evaluated by biopsy or surgery and were confirmed as PCa with no false positives. Morigi et al. also showed the superiority of 68Ga PSMA-HBED-CC over 18F FCH in PET/CT. Detection rates 68Ga PSMA-HBED-CCPET/CT in multiple studies are higher than for rates reported in the literature for 11C Choline, 18F Choline, and 11C Acetate \[20\]. Most importantly the detection rates 68Ga PSMA-HBED-CCPET/CT in patients with low PSA (\<0.5 ng/ml) are more favorable.

Thus preclinical and clinical studies show that 68Ga PSMA-HBED-CC PET/CT is a promising radiotracer for the early detection of metastatic or recurrent PCa even with low serum PSA levels.
Methods, systems, and devices are provided for monitoring and displaying medical parameters for a patient. In one embodiment, a display screen can include information related to a physiological parameter being measured from a patient. The information can include a current value based on values of the physiological parameter gathered from the patient over a period of time. The display screen can indicate whether or not the current value is within a predetermined normal range for the physiological parameter and whether or not the current value is within a predetermined goal range for the physiological parameter. The goal range can be nested within the normal range. If the current value moves outside the normal range, an alarm can be triggered. A goal alarm can be triggered if the current value is within the normal range but falls outside the goal range.
MicroRNAs (miRNAs) have emerged as promising biomarkers for acute myocardial infarction (AMI). There is an urgent imperative to develop analytical methodologies capable of intelligently discerning multiple circulating miRNAs. Here, we present a dual miRNA detection platform for AMI using DNA logic gates coupled with an electrochemiluminescence (ECL) response. The platform integrates DNA truncated square pyramids as capture probes on gold-deposited electrodes, enabling precise quantification of miRNA associated with AMI. The cyclic enzymatic signal amplification principle of strand displacement amplification enhances the miRNA detection sensitivity. AND and OR logic gates have been successfully constructed, enabling intelligent identification of miRNAs in AMI. Calibration curves show strong linear correlations between ECL intensity and target miRNA concentration (10 fM to 10 nM), with excellent stability in consecutive measurements. When applied to clinical serum samples, the biosensor exhibits consistent performance, underscoring its reliability for clinical diagnostics. This innovative approach not only demonstrates DNA nanotechnology's potential in biosensing but also offers a promising solution for improving AMI diagnosis and prognosis through precise miRNA biomarker detection.
The present invention relates to the prevention and treatment of implant associated complications; e.g. foreign body response (FBR). High mechanical stress at the implant-tissue interface activates a sustained inflammatory response, which is primarily responsible for implant associated complications and implant failure. In particular, described herein are apparatuses, devices, and compositions containing inhibitors of mechanotransduction, and methods of making and using such apparatuses, devices and compositions. These apparatuses, devices, compositions, and methods are useful for preventing or reducing unwanted fibrosis, inflammation or cancer that result from implantation of a biomedical implant in an individual. One aspect of the invention provides a biomedical device including an effective amount of a composition containing a mechanotransduction inhibitor for preventing, inhibiting or treating implant associated complications.
PURPOSE:The titled remedy containing a proteolytic enzyme as an active constituent without side effects. CONSTITUTION:A preventing agent and remedy for diseases, obtained by combining one or two or more proteolytic enzymes, e.g. trypsin, alpha-chymotrypsin, bromelain or papain, suitably, and effective for hyperlipemia, hypolipemia and arteriosclerosis. The dosage form thereof is an oral agent of a tablet, capsule, powder or granule, etc. or a parenteral agent of an injection, suppository or ointment, etc. The preventing agent and remedy may be used together with another agent, e.g. a drug for the liver or kidney, antibiotic substance, immunological activator, hypotensive agent, etc. The dose thereof is 10-5,000mg/day/ human.
After obtaining informed consent, patients enrolled in the 'study drug' arm of the trial will receive Ketamine (1 mg/ml solution prepared in normal saline) infusion at a rate of 20 mg/h for a period of 24 hours. The infusion will start at a rate of 5 mg/h, and then gradually tapered up during the first 3 hours by 5 mg an hour. Similarly, the infusion rate will be gradually tapered down at a rate of 5 mg/h during the last 3 hours of infusion. The patients randomized to the 'placebo arm' of the trial will receive normal saline infusion at the same rates. In order to prevent the psychogenic adverse effects associated with Ketamine, the patients will be administered Midazolam at a dose of 1 mg IV every 4 hours. Midazolam will also be administered at the same rate to the patients randomized to the placebo arm. Blood Ketamine levels will be measured before starting the treatment, and daily while the infusion is on. While receiving treatment, the patients will be admitted to the telemetry floor in the hospital, on a monitored bed.
Name：Human umbilical cord mesenchymal stem cells Specification: 30 ml/bag Dosage: 1×106cells/kg, 5×106cells/kg, 10×106cells/kg Usage: Intravenous infusion The stem cells used in this study are human umbilical cord mesenchymal stem cells (hUC-MSCs), which are derived from umbilical cords donated by healthy mothers who have given birth in maternity hospitals. hUC-MSCs are extracted, processed, cultured and harvested from umbilical cord donors recruited by laboratories complying with the GMP standards. hUC-MSCs cell suspensions that have passed the quality control will be put into bags and transported to the hospitals for use by the subjects of the present clinical study.
INCB7839 dosing will begin at 120 mg/m2/dose BID which is equivalent to the adult RP2D (200 mg PO BID) based on a typical adult size of 1.67m2. The INCB7839 dose may be decreased to 80 mg/m2/dose BID if the staring dose is not tolerable. 28 consecutive days (4 weeks) will constitute one course. Patients may continue to receive INCB7839 for 26 courses (approximately 2 years).
An injectable ivermectin composition having a programmable release rate and providing multiple concentration peaks of active ivermectin to produce a sequence of ivermectin release pulses into the blood of cattle and horses. The composition comprises a solution of 0.2%-10% w/w of ivermectin in a solvent selected from propyleneglycol and a mixture of glycerile caprylate, caproate and caprate, such as glycerides of caproic, caprilic and capric acids in equal parts. The solution is used as a vehicle for suspending microspheres 100 nm-200  mu m in diameter of a degradable polymer containing between 0.5% and 50% of ivermectin. The microspheres may be formed from polylactic acid, polyglycolic acid or a copolymer of polylactic-polyglycolic acid. The programmable multi-pulse release system may also be obtained with a biodegradable matrix selected from hardenable natural polymers, such as gelatin or albumin, apart from the copolymers of lactic and gycolic acids. The polymers may be subjected to a hardening process to increase resistance to biological agents, for example, a solution of glutaraldehyde or alum or by heating the proteins up to coagulation temperature. In one embodiment, gelatin microspheres loaded with ivermectin are treated in an acqueous solution of glutaraldehyde at 25% during 24 hours and then suspended in the solvent. Another embodiment includes a suspension of ivermectin-loaded microspheres of DL-lactic-glycolic 1:1 copolymer. This monomer ratio may be altered to enhance resistance to erosion.
This group will engage have usual diabetes care without intervention. They will fill out all questionnaires, attend clinic visits and provide A1C samples at the same times as the participants in the other groups.
The subjects will receive 1 drinkable vial (4mL) per day during 14 days. Each vial contains 10e4 Colony-forming units (CFUs) of Nyaditum resae®.
PROBLEM TO BE SOLVED: To provide a terminal which can more efficiently input the physical situation of a patient and which can easily grasp a part where the physical situation is generated. SOLUTION: In the portable terminal, an operator indicates the part to which the physical situation is inputted on a human body diagram by tapping it with a pen. Then, the list of the physical situations which probably occur in the part is displayed in a pop up list. When the physical situation to be inputted is selected, the pop up list of the value of the physical situation is displayed. The value becomes a value showing the degree of 'heavy' and 'light'. When the operator selects the degree from the pop up list, the value is inputted as the physical situation. Thus, the operator can easily input the physical situation only by tapping with the pen and the like.
The purpose of the current pilot study will be to utilize implementation intentions to increase patient compliance with appointment attendance. It is anticipated that participants who take an active role in their plan and utilize the implementation intention procedures will be more likely to make and attend the appointments suggested by their treating clinician. Sixty participants will be recruited to participate in the research project. Participants in the current study will be individuals referred for a secondary Traumatic Brain Injury (TBI) screen. This appointment serves to develop the plan of care that will be used for determination of the treatments that would be beneficial to the Veteran and as such the appointments necessary for further assessment or treatment in affiliated clinics (i.e. mental health, physical therapy, neuropsychology). Twenty participants will serve as controls who will receive treatment planning as usual. Twenty participants will receive treatment as usual but will be asked to contact the clinics directly to make their appointments. Twenty participants will be provided with a simple implementation intention induction. The simple induction will consist of the creation of "what/when/where" statements surrounding their intention to call to schedule and to attend medical appointments associated with their care. Research staff will then monitor the participants' appointment schedule daily to determine if they made the appropriate appointments and subsequently attended those appointments. Primary data for the examination will be these yes/no data points as to whether the participant successfully adhered to their initial intention to schedule the prescribed appointments. Additionally, for those who schedule the prescribed appointments, the latency in days from the time they indicated they intended to make their appointments will serve as a measure of their compliance. Across all groups, attendance at those appointments will be recorded to determine if the procedures lead to an increase in their attendance at their appointments compared to the treatment as usual group. This pilot project will provide valuable initial data as to the potential effectiveness of a simple, cost-effective means of increasing appointment attendance. If successful, it could lead to cost savings to the VA system and a decrease in the appointment wait time for Veterans by increasing the utilization of available appointments.
There will be four in-person group sessions (1/month), two including the participants' partners, and all with on-site child care. Sessions will include preparation of a healthy meal (hands-on) and discussions of mindful eating, balanced meals, portion sizes, and preparing food at home, under a dietitian's supervision. Sessions will also include a one-hour physical activity information/practice session with a kinesiologist. Participants will track daily step counts with a pedometer and aim to eventually reach more than 10,000 steps/day. They will also receive instruction and demonstration from a kinesiologist of some simple resistance exercises they may perform at home. Between sessions, participants will receive advice and support through a study-specific website and telephone calls.
BACKGROUND AND OBJECTIVES: Cardiopulmonary Rehabilitation (CR) is crucial for managing conditions like congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), and post-COVID-19 complications. This review examines CR practices in the Middle East and North Africa (MENA) region, exploring challenges, disparities, and emerging trends.
METHODS: A comprehensive literature search was conducted in PubMed, Scopus, and Web of Science to identify studies published between date of inception and April 24th, 2024, focusing on CR programs, outcomes, challenges, and strategies specific to the MENA region. Data extraction included study design, population characteristics, CR interventions, and key findings.
RESULTS: CR programs in the MENA region vary widely in scope and execution. While efforts are underway to integrate CR services into national healthcare policies, significant challenges persist, including limited infrastructure, shortages of trained professionals, and cultural barriers. Emerging trends include the use of telehealth and digital monitoring tools to expand access to CR services and policy reforms aimed at improving service delivery and patient access.
CONCLUSION: CR plays a crucial role in improving the quality of life and health outcomes for cardiopulmonary patients, including those in the MENA region. However, significant challenges hinder the widespread adoption and effectiveness of CR programs. Addressing these challenges requires efforts to increase public education, reduce costs, expand funding, and enhance interprofessional collaboration. Future research should assess virtual rehabilitation, cultural adjustments, and long-term outcomes to tailor interventions to MENA's needs, ultimately enhancing CR accessibility and patient outcomes.
Currently there existed no specific diagnostic test of Parkinson's Disease. Accurate diagnosis is of great interest because of the reduction in health cost and disease co-morbidity, improvement in effective treatment course and avoidance of un-necessary intervention. Our preliminary result showed superior performance from diffusion kurtosis imaging, a new development in MRI since 2007, on the diagnosis of Parkinson's Disease when compared to conventional diffusion MRI. The study proposes to validate the diagnostic value of diffusion kurtosis in major basal ganglia regions using a cross-sectional study and to assess the prognostic value through 3-year longitudinal follow-up. Furthermore, the iron content as well as global white matter involvement in both PD and PD plus syndrome patients will be assessed. The difference in MRI information between PD and PD plus syndrome patients will then be addressed in a comprehensive manner.

One hundred and twelve patients with Parkinson's Disease will be recruited in the first year and followed up for 3 years. Another 112 healthy controls will be included. This is to validate the diagnosis and assess the prognosis. Another 30 patients with Parkinson's Disease, 15 patients with progressive supranuclear palsy and 15 patients with multiple system atrophy will be recruited in the 2nd year for differential diagnosis. The imaging protocol will include both diffusion tensor and diffusion kurtosis imaging. Susceptibility weighted imaging will be included for iron content estimation. The targeted anatomy will include regional changes in basal ganglia, midbrain as well as thalamus, and global white matter changes using tract based spatial statistics. The statistical analysis will use receiver operative characteristics to assess the diagnostic performance, Spearman's ranked correlation for correlation with disease severity and net reclassification improvement for differential diagnosis. The prognostic value will be determined by the decline rate and the quality of life.

The end points of the project are to differentiate patients of PD from PD plus syndrome, and to predict the clinical outcomes using diffusion MRI. Patent application will be filed in the first year. The analysis of medical device software and software life cycle processes and the evaluation of risk management to medical devices will be filed at the end of the third year.